
Indraprastha Medical (INDRAMEDCO) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
3.3B
Gross Profit
1.2B
36.13%
Operating Income
504.1M
15.10%
Net Income
410.1M
12.29%
Balance Sheet Metrics
Total Assets
8.5B
Total Liabilities
2.5B
Shareholders Equity
6.0B
Debt to Equity
0.43
Cash Flow Metrics
Revenue & Profitability Trend
Indraprastha Medical Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 13.6B | 12.0B | 10.6B | 8.6B | 6.0B |
Cost of Goods Sold | 8.6B | 7.9B | 7.2B | 6.0B | 4.5B |
Gross Profit | 4.9B | 4.1B | 3.4B | 2.6B | 1.5B |
Gross Margin % | 36.4% | 34.3% | 32.4% | 30.7% | 25.1% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 1.2B | 969.6M | 602.1M | 320.9M |
Other Operating Expenses | 2.5B | 1.4B | 1.3B | 1.1B | 912.8M |
Total Operating Expenses | 2.5B | 2.5B | 2.2B | 1.7B | 1.2B |
Operating Income | 2.0B | 1.5B | 1.1B | 851.3M | 76.6M |
Operating Margin % | 14.7% | 12.8% | 10.5% | 9.9% | 1.3% |
Non-Operating Items | |||||
Interest Income | - | 168.9M | 100.3M | 31.2M | 6.8M |
Interest Expense | 62.7M | 10.6M | 4.6M | 6.1M | 0 |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 2.2B | 1.7B | 1.2B | 790.7M | 42.9M |
Income Tax | 553.3M | 421.5M | 310.3M | 204.5M | 19.6M |
Effective Tax Rate % | 25.6% | 25.4% | 26.5% | 25.9% | 45.7% |
Net Income | 1.6B | 1.2B | 861.5M | 586.2M | 23.3M |
Net Margin % | 11.9% | 10.3% | 8.1% | 6.8% | 0.4% |
Key Metrics | |||||
EBITDA | 2.7B | 2.1B | 1.6B | 1.2B | 383.2M |
EPS (Basic) | ₹17.56 | ₹13.52 | ₹9.40 | ₹6.39 | ₹0.25 |
EPS (Diluted) | ₹17.56 | ₹13.52 | ₹9.40 | ₹6.39 | ₹0.25 |
Basic Shares Outstanding | 91679954 | 91673000 | 91673000 | 91673000 | 91673000 |
Diluted Shares Outstanding | 91679954 | 91673000 | 91673000 | 91673000 | 91673000 |
Income Statement Trend
Indraprastha Medical Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 614.8M | 616.0M | 522.6M | 417.4M | 249.2M |
Short-term Investments | 2.7B | 1.7B | 807.3M | 290.5M | 46.9M |
Accounts Receivable | 754.5M | 584.0M | 682.4M | 433.5M | 673.9M |
Inventory | 69.9M | 75.3M | 84.5M | 99.9M | 87.4M |
Other Current Assets | 166.0M | 111.5M | 108.6M | 42.0M | 72.2M |
Total Current Assets | 4.3B | 3.1B | 2.2B | 1.6B | 1.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.3B | 2.6B | 2.1B | 1.9B | 1.9B |
Goodwill | 5.9M | 10.5M | 9.6M | 17.1M | 33.8M |
Intangible Assets | - | 10.5M | 9.6M | 17.1M | 33.8M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 27.9M | 51.7M | 70.6M | 25.8M | 20.3M |
Total Non-Current Assets | 4.2B | 4.2B | 3.3B | 3.0B | 2.9B |
Total Assets | 8.5B | 7.2B | 5.6B | 4.6B | 4.3B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 1.2B | 1.4B | 981.8M | 767.5M | 917.5M |
Short-term Debt | 22.2M | 16.8M | 24.8M | 28.3M | 25.1M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 210.3M | 62.3M | 59.6M | 41.3M | 54.9M |
Total Current Liabilities | 1.8B | 1.7B | 1.3B | 935.0M | 1.2B |
Non-Current Liabilities | |||||
Long-term Debt | 305.4M | 322.7M | 0 | 24.8M | 53.0M |
Deferred Tax Liabilities | 153.9M | 197.2M | 199.8M | 231.9M | 222.6M |
Other Non-Current Liabilities | - | 8.8M | 16.6M | 17.9M | - |
Total Non-Current Liabilities | 762.3M | 800.6M | 460.6M | 427.7M | 433.0M |
Total Liabilities | 2.5B | 2.5B | 1.8B | 1.4B | 1.6B |
Equity | |||||
Common Stock | 916.7M | 916.7M | 916.7M | 916.7M | 916.7M |
Retained Earnings | - | 3.6B | 2.6B | 2.0B | 1.4B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 6.0B | 4.8B | 3.8B | 3.3B | 2.7B |
Key Metrics | |||||
Total Debt | 327.6M | 339.5M | 24.8M | 53.1M | 78.1M |
Working Capital | 2.5B | 1.4B | 934.5M | 639.3M | 255.3M |
Balance Sheet Composition
Indraprastha Medical Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 2.2B | 1.7B | 1.2B | 790.7M | 42.9M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -188.2M | 147.9M | -219.5M | 247.0M | 118.6M |
Operating Cash Flow | 1.8B | 1.7B | 856.6M | 1.0B | 162.8M |
Investing Activities | |||||
Capital Expenditures | -363.3M | -693.9M | -445.8M | -294.8M | -209.6M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -363.3M | -693.9M | -445.8M | -535.8M | -198.8M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -407.3M | -275.4M | -228.4M | -2.6M | -2.4M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | 0 |
Financing Cash Flow | -407.3M | -275.4M | -228.4M | -2.6M | -2.4M |
Free Cash Flow | 1.2B | 1.3B | 998.9M | 648.2M | 58.5M |
Net Change in Cash | 1.0B | 681.4M | 182.4M | 474.2M | -38.4M |
Cash Flow Trend
Indraprastha Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.50
Forward P/E
186.12
Price to Book
7.15
Price to Sales
3.11
PEG Ratio
186.12
Profitability Ratios
Profit Margin
12.21%
Operating Margin
17.25%
Return on Equity
26.98%
Return on Assets
18.90%
Financial Health
Current Ratio
2.41
Debt to Equity
5.49
Beta
0.59
Per Share Data
EPS (TTM)
₹17.56
Book Value per Share
₹65.04
Revenue per Share
₹149.83
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
indramedco | 42.7B | 26.50 | 7.15 | 26.98% | 12.21% | 5.49 |
Max Healthcare | 1.2T | 115.26 | 13.09 | 12.10% | 15.31% | 32.09 |
Apollo Hospitals | 1.0T | 72.09 | 12.70 | 18.85% | 6.63% | 90.89 |
Shalby | 21.8B | 1,126.78 | 1.99 | 0.19% | 0.57% | 9.69 |
Dr. Agarwal's Eye | 20.7B | 37.83 | 9.87 | 29.80% | 13.76% | 158.94 |
GPT Healthcare | 13.0B | 26.09 | 5.25 | 21.41% | 12.26% | 14.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.